Pre-clinical AAV production and optimization
Not as easy as it looks!
Presented by Nature Research Custom Media
Produced by Genscript
Speaker: Dr. Stephen Hughes, Director of New Platform Development at Genscript
- Introduction to AAV in gene therapy.
- Some recent advances in viral vector production.
- Current challenges and solutions of pre-clinical AAV production.
Adeno-associated virus (AAV) is the most popular vector of choice for gene therapy because of its low immunogenicity and ability to infect numerous cells and tissue types. However, with hundreds of gene therapy trials ongoing, manufacturing large quantities of viral vectors is becoming an increasing challenge.